X4 Pharmaceuticals (XFOR) Misses Q2 EPS by 17c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $-55.7 million.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• KeyBanc Starts CF Industries (CF) at Underweight
• Copart (CPRT) Misses Q4 EPS by 4c